eFFECTOR Therapeutics Inc. Common Stock EFTR · Stock Open eFFECTOR Therapeutics Inc. Common Stock in new tab
eFFECTOR Therapeutics Inc. Common Stock Analysis (EFTR)
Is eFFECTOR Therapeutics Inc. Common Stock a good investment? eFFECTOR Therapeutics Inc. Common Stock (EFTR) is currently trading at 0.000200 USD.
Earnings Schedule: eFFECTOR Therapeutics Inc. Common Stock is expected to release its next earnings report on Nov. 17, 2026. The market consensus estimate for Forward EPS is -2.25.
Investor FAQ
Does eFFECTOR Therapeutics Inc. Common Stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is eFFECTOR Therapeutics Inc. Common Stock?
eFFECTOR Therapeutics Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 17, 2026. The company currently has a trailing EPS of -5.03.
Company Profile
eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. The company's lead product candidate includes Zotatifin, an inhibitor of eIF4A, which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as has completed Phase 2 clinical trial in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. It also develops Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. It has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California.
| Split Date | Split Ratio to 1 |
|---|---|
| Jan. 12, 2024 | 1:25 |
Community Discussion